The future of drug discovery lies in an automated world where the workflows for biological assays, chemical synthesis and data analysis are connected by flexible, mobile and modular hardware, integrated with software solutions that will interface with scientists for increased efficiency and productivity (the realisation of Industry 4.0). This article…
List view / Grid view
Dr Mark Wigglesworth (AstraZeneca)
Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.